On 16 March, CEO Jan Alenfall will present Follicum at Sedermeradagen in Lund at 16.20-16.50. Sedermeradagen offers an opportunity for investors to meet with companies in the micro- and smallcap segment in Sweden. More information in Swedish
Follicum appoints Maria Ekblad Director R&D as of January 2016. Maria Ekblad has more than twenty years of experience from the pharmaceutical industry where she has held various management positions; the latest as Director Preclinical Development at Active Biotech AB in Lund. At Follicum Ekblad will be responsible for the preclinical development as well as […]
Follicum report from World Conference on Hair Research, November 18-21, 2015 in Miami, USA by CEO Jan Alenfall The 2015 WCHR Scientific meeting has the overall goal of presenting new research, sharing experiences, and discussing the advancement and knowledge of hair growth as well as skin-, hair- and scalp diseases. In addition it is a […]
Follicum attended the French Swedish Life Science Day 2015 on 20 October in Paris. The company presented their research projects and had the opportunity to meet with investors and representatives from pharmaceutical companies. The purpose of the meetings was to initiate contacts for future capital investments and potential collaborations. There was significant interest in Follicum’s drug candidates.
Follicum has received a preliminary approval – a so called “Intention to Grant” – by the European Patent Office (EPO) regarding the company’s patent application for stimulation of hair growth. To read the full press release (in Swedish) please click here. For more information about Follicum’s research results, please contact: Jan Alenfall, CEO Tel +46 (0)46 19 21 […]
The German research group which has generated important parts of Follicum’s research data on human skin will present their results both as a poster and in an oral presentation at the World Congress for Hair Research. The congress takes place in Miami in Florida, USA, on 18-21 November 2015. To read the full press release […]
As previously communicated, Follicum’s intention is to start a clinical phase I/IIa study around year-end 2015/early 2016. We can now announce that a cooperation with the Clinical Research Center for Hair and Skin Science (“CRC”) in Berlin, Germany, has been initiated regarding our planned clinical phase I/IIa study. Follicum’s intention is to submit an application […]
Follicum announced in March 2015 that they had started two larger toxicity studies to add information to the two short time toxicity studies and continue development. The short time studies were finalized in February 2015, and showed no adverse effects. The two larger toxicity studies have now been finished according to plan, showing very promising […]
Follicum announce today that the synthesis of the peptide has been completed. The peptide is the active ingredient of the product planned to be used in the clinical Phase I/IIa study. Production of product for the clinical Phase I/IIa study Follicum announced in early June that the company had signed an agreement with the peptide […]
Follicum’s half-year report 2015 (1 January to 30 June) is now published. Click here to open the report (in Swedish).